Companies › Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Nov 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| MK-4208 (TERN-701) ABL kinase inhibitor | BCR, ABL1 | Phase 1 | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Nov 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06163430 | MK-4208 (TERN-701) | Phase 1 | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Oncology | Nov 2029 |
Ascentage Pharma Group Il-Yang Pharm. Takeda Incyte Biosciences International Sàrl Enliven Therapeutics Novartis Taiho Pharmaceutical Otsuka Bayer
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.